Navigation Links
Study examines outcomes of screening mammography for age, breast density, hormone therapy
Date:3/18/2013

A study that compared the benefits and harms of the frequency of screening mammography to age, breast density and postmenopausal use of hormone therapy (HT) suggests that woman ages 50 to 74 years who undergo biennial screenings have a similar risk of advanced-stage disease and a lower cumulative risk of false-positive results than those who get mammograms annually, according to a report published Online First by JAMA Internal Medicine, a JAMA Network publication.

In 2009, the U.S. Preventive Services Task Force issues guidelines that biennial mammography, rather than the previously recommended mammography every one to two years, be performed for women ages 50 to 74, but the updated guidelines did not consider the influence of breast cancer risk factors beyond age, according to the study background.

Karla Kerlikowske, M.D., of the University of California, San Francisco, and colleagues sought to determine whether the benefits, such as early detection, and the harms, such as a false-positive mammography result or biopsy recommendation, differ among women undergoing screening mammography according to age, breast density and postmenopausal HT use.

Researchers analyzed data collected from January 1994 to December 2008 from mammography facilities in community practice that participate in the Breast Cancer Surveillance Consortium (BCSC) mammography registries. Data were collected from 11,474 women with breast cancer and 922,624 without breast cancer.

The authors found that biennial vs. annual mammography for women ages 50 to 74 was not associated with an increased risk of advanced-stage or large-size tumors regardless of a women's breast density or HT use. However, the results indicate that among women ages 40 to 49 years with extremely dense breasts, biennial mammography vs. annual was associated with an increased risk of advanced-stage cancer (odds ratio [OR], 1.89) and large tumors (OR, 2.39).

Study results also
'/>"/>

Contact: Elizabeth Fernandez
Elizabeth.Fernandez@ucsf.edu
415-514-1592
The JAMA Network Journals
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Parents Worries About HPV Vaccine on the Rise: Study
2. Nursing Shortage May Harm Infants in Intensive Care, Study Says
3. Study Probes Use of Filter Device to Stop Deadly Blood Clots
4. Patients Health Care Costs Unaffected by Doctors Sex: Study
5. Study confirms difference in radical prostatectomy outcomes between surgeons
6. Consumers View Foods With Green Labeling as Healthier: Study
7. Study shows rising rate of propofol abuse by health care professionals
8. UK study: Epigenetic changes play a key role in development of chemo resistance in BCa
9. New study points to the aggressive potential of small kidney tumors, advocates treatment
10. New study: Incidence and mortality of PCa after termination of PSA-based screening
11. Study shows community approach effective in fight against diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Vegas Hotel Escapes, the premier Las ... new vacation packages for the upcoming memorial day ... for this patriotic holiday will be pleased to ... new special pricing available on VegasHotelEscapes.com's website. , ... the lowest prices possible on vacation packages to ...
(Date:5/23/2013)... May 23, 2013 Funeral Financials is ... Day to the EOD Memorial Foundation Funeral ... the greatest victims from the war. , According ... in 1941 before the U.S. was even at war. ... are identified with the Explosive Ordnance Disposal Badge. EOD ...
(Date:5/23/2013)... 23 (HealthDay News) -- A modified version of ... brain tumors, preliminary research suggests. Scientists at ... known as PVSRIPO, uses an engineered form of ... but attacks cancer cells. The therapy shows promise ... and aggressive brain tumor, they said. "These ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 “Talk. They ... campaign that empowers parents to talk to children as ... underage drinking, was launched today by the Substance Abuse ... kickoff occurred in conjunction with SAMHSA’s 2013 National Prevention ... and action around, substance abuse and mental health issues. ...
(Date:5/23/2013)... next generation genomic analysis to determine that some of ... origins, which may help in predicting cancer progression. The ... Research . , "This is the first study to ... Gleason patterns in the same tumor allowing us to ... M.D., Mayo Clinic pathologist and one of the authors ...
Breaking Medicine News(10 mins):Health News:Funeral Financials Asks Americans to Donate their Memorial Day Beer Money to Help EOD Scholarship 2Health News:Funeral Financials Asks Americans to Donate their Memorial Day Beer Money to Help EOD Scholarship 3Health News:Modified Polio Virus May Help Fight Brain Tumors, Study Suggests 2Health News:New Campaign to Help Parents Talk to Younger Children About the Dangers of Underage Drinking 2Health News:Mayo Clinic genomic analysis lends insight to prostate cancer 2
... In ... of Technical Personnel in Ophthalmology (ATPO) proudly launched a new tool for ophthalmic professionals: ... , ... Paul, MN (Vocus) November 10, 2009 -- Compact, informative, and convenient are just a ...
... Darden Food Supplier Eliminates Workers Health and Retirement Benefits ... members from Teamster Local Union 890 presented Darden Restaurant Group, ... a letter today directed to Darden CEO Clarence Otis. In ... workers from Hollister, CA are seeking justice after a key ...
... Pa., Nov. 10 InfoLogix, Inc. (Nasdaq: IFLG ... for the healthcare and commercial industries, today announced that ... to NASDAQ,s stockholder approval requirements, in accordance with NASDAQ ... this exception to complete a proposed plan of restructuring, ...
... Nov. 10 Roxane Laboratories, Inc. announced today the ... Perindopril Erbumine Tablets, 2mg, 4mg and 8mg by the ... available in bottles of 100 for immediate shipment to ... Tablets are AB rated to ACEON® (perindopril erbumine) tablets. ...
... , ... Rounds -- "What I,ve Learned About the Throwing Arm in the Last 30 Years" ... Gulf Breeze, Fla. (Vocus) November ... Andrews Institute will hold its inaugural Grand Rounds presentation on November, 19, 2009 at ...
... of vascular risk can be simplified, researchers say ... gauge blood cholesterol to determine vascular disease risk can ... measures levels of either total or high-density lipoprotein (HDL, ... that help transport cholesterol), without the need to have ...
Cached Medicine News:Health News:JCAHPO/ATPO Pocket Guide Launches for Eye Care Professionals 2Health News:JCAHPO/ATPO Pocket Guide Launches for Eye Care Professionals 3Health News:Teamsters Look to Darden Restaurant Group for Justice 2Health News:InfoLogix Announces Receipt of NASDAQ Waiver for Stockholder Approval of Restructuring and Extension to Stockholder's Equity Requirement 2Health News:InfoLogix Announces Receipt of NASDAQ Waiver for Stockholder Approval of Restructuring and Extension to Stockholder's Equity Requirement 3Health News:InfoLogix Announces Receipt of NASDAQ Waiver for Stockholder Approval of Restructuring and Extension to Stockholder's Equity Requirement 4Health News:InfoLogix Announces Receipt of NASDAQ Waiver for Stockholder Approval of Restructuring and Extension to Stockholder's Equity Requirement 5Health News:Roxane Laboratories, Inc. Announces the Launch of Perindopril Erbumine Tablets 2Health News:Orthopaedic Surgeon and AOSSM President Dr. James Andrews to Discuss Injury Prevention 2Health News:Orthopaedic Surgeon and AOSSM President Dr. James Andrews to Discuss Injury Prevention 3Health News:Cholesterol Measurements May Be Made Easier 2
(Date:5/23/2013)... , May 23, 2013  Intercept Pharmaceuticals, Inc. ... biopharmaceutical company focused on the development and commercialization of ... such as primary biliary cirrhosis, today announced that ... Executive Officer, will present at the Deutsche Bank Securities ... on Wednesday, May 29, 2013 at 4:10 ...
(Date:5/23/2013)...  Omeros Corporation (NASDAQ: OMER ) ... (IND) to evaluate OMS824 in Huntington,s disease has ... Administration (FDA). OMS824 selectively inhibits phosphodiesterase 10 (PDE10), ... linked to a wide range of diseases that ... has shown promising results in animal models directly ...
(Date:5/23/2013)... 23, 2013  MedVantx, Inc., the company that has ... announced today the Company has completed a major expansion ... pharmaceutical products and the upgrade of its systems to ... in its specialty home delivery pharmacy in ... pharmaceutical manufacturers, physicians, health systems and payors novel distribution ...
Breaking Medicine Technology:Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 2Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 3Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 4MedVantx Achieves Significant Milestone of Managing $1.5B in Prescription Medications and Completes Facilities Expansion While Upgrading To Offer Current Good Manufacturer Practices (cGMP)-level Quality Systems in their Home Delivery Pharmacy 2MedVantx Achieves Significant Milestone of Managing $1.5B in Prescription Medications and Completes Facilities Expansion While Upgrading To Offer Current Good Manufacturer Practices (cGMP)-level Quality Systems in their Home Delivery Pharmacy 3
... ... Study, Pharmacokinetic Study Demonstrates Lack of Systemic Exposure of XIAFLEX, ... Conference call scheduled for today, June 3, at 8:45 a.m. Eastern Time, ... positive top-line,efficacy and safety results from the CORD I and CORD II phase ...
... 2 Alliance,Pharmaceutical Corp. (OTC Bulletin Board: ALLP) announced ... the two proposals put to the,shareholders at its Annual ... first proposal related to the re-election of each of ... additional term of one year or,until their successors are ...
Cached Medicine Technology:Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 2Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 3Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 4Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 5Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 6Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 7Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 8Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 9Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 10Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 11Alliance Pharmaceutical Corp. Announces Approval of Proposed Actions at Annual Shareholders Meeting 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: